Molecular testing of sensitizing EGFR mutations, BRAF V600E, as well as ALK, ROS1, and NTRK fusions, is now standard-of-care for patients with advanced NSCLC [10], as is testing for the EGFR T790M mutation upon resistance to first- or second-generation EGFR tyrosine kinase inhibitor therapy [11,12,13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.